AI assistant
Anteris Technologies Global Corp. — Capital/Financing Update 2022
Aug 1, 2022
33869_rns_2022-08-01_cd1451c2-abbb-4893-837e-ad64ab79f273.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT
2 August 2022
CONVERSION OF SECURITIES
Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR; Anteris or the Company ) announces that in accordance with the Convertible Security and Share Purchase Agreement dated 6 January 2021 ( Agreement) as amended between Anteris Technologies Ltd and Mercer Street Global Opportunity Fund, LLC ( Investor ), the Investor has provided notice to convert a portion of its third tranche of convertible notes with a face value of $1,350,000 into ordinary shares. This investment in the Company foregoes the requirement for the Company to repay this amount. The remaining portion of the third tranche of convertible notes with a face value of $1,350,000 will be repaid in cash.
In accordance with the Agreement, the conversion price is 90% of the five-day VWAP of the Shares up to the issue of the conversion notice being $22.91. This compares to a closing price of $10.01 on 12 April 2021, the date of issue of the third tranche of convertible notes.
ENDS
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.
Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.
Anteris’ DurAVR[™] 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[™] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.
Authorisation and Additional information
This announcement was authorised by the Board of Directors.
For more information:
Hannah Howlett WE Communications E: [email protected] P: +61 4 5064 8064 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech
LinkedIn: https://www.linkedin.com/company/anteristech
Anteris Technologies Ltd Registered Office:
Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service
T +61 1300 550 310 | F +61 1300 972 437 | E [email protected] | W anteristech.com
==> picture [95 x 51] intentionally omitted <==
Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga